Daily Cosmetic Research Analysis
Today’s top cosmetic and aesthetic surgery papers emphasize safety and outcomes: a multicenter prospective study validates supramastoid fascia as a stable autologous graft for rhinoplasty, a propensity-matched analysis supports oncologic adequacy of transoral robotic thyroidectomy with scarless benefits, and a large office-based audit demonstrates safe intravenous sedation with strict protocols.
Summary
Today’s top cosmetic and aesthetic surgery papers emphasize safety and outcomes: a multicenter prospective study validates supramastoid fascia as a stable autologous graft for rhinoplasty, a propensity-matched analysis supports oncologic adequacy of transoral robotic thyroidectomy with scarless benefits, and a large office-based audit demonstrates safe intravenous sedation with strict protocols.
Research Themes
- Autologous graft innovation in rhinoplasty
- Scarless oncologic surgery and cosmetic trade-offs
- Patient safety and anesthesia in office-based aesthetic procedures
Selected Articles
1. Supramastoid Fascia as an Autologous Donor Site Alternative for Moderate Dorsal Augmentation: A Multicenter Prospective Study.
In a multicenter prospective cohort (n=73), supramastoid fascia provided stable moderate dorsal augmentation with low resorption (≈9% at 36 months), high FACE-Q satisfaction, and no donor-site morbidity. Objective 3D photogrammetry and ultrasound confirmed sustained projection without irregularities.
Impact: Offers a minimally invasive autologous option with objective long-term stability, addressing a practical need in rhinoplasty where implant choice and resorption risk are central.
Clinical Implications: Surgeons can consider supramastoid fascia for moderate dorsal augmentation to balance stability and aesthetics while minimizing visible scarring and donor morbidity.
Key Findings
- Dorsal height increased early and remained stable through 36 months (no significant decline after 12 months).
- Mean resorption was 8.6% at 12 months and 9.4% at 36 months.
- FACE-Q satisfaction exceeded 80 across domains with no late decline.
- No graft displacement, surface irregularity, or donor-site morbidity observed.
Methodological Strengths
- Multicenter prospective design with predefined timepoints up to 36 months
- Objective outcomes via 3D photogrammetry and 15-MHz ultrasound
- Longitudinal analysis using repeated-measures ANOVA and mixed-effects models
Limitations
- Nonrandomized observational design without a comparator graft
- Longer-term follow-up beyond 36 months and broader ethnic representation are needed
Future Directions: Head-to-head randomized or matched comparative studies versus other autologous/alloplastic grafts and evaluation across diverse ethnic nasal anatomies.
BACKGROUND: Autologous fascia has been widely applied in rhinoplasty, yet prospective data on the supramastoid donor site remain scarce. This region provides a dense, pliable fascial layer with concealed scarring, potentially suitable for moderate nasal dorsal augmentation. OBJECTIVES: To prospectively evaluate the clinical outcomes, long-term stability, and patient satisfaction of supramastoid fascia as an autologous graft material for dorsal augmentation. METHODS: This multicenter observational study enrolled patients between June 2022 and April 2024. Dorsal projection and fascial thickness were measured by 3D photogrammetry and 15-MHz ultrasound at 1, 6, 12, 24, and 36 months, with patient satisfaction assessed using the FACE-Q Rhinoplasty Module. Longitudinal changes were analyzed using repeated-measures ANOVA and linear mixed-effects models. RESULTS: Among 73 patients, 67 (91.8%) completed ≥12 months of follow-up; 65% were observed beyond 24 months and 19% to ≥36 months. Dorsal height increased significantly at 1 month and remained stable through 36 months (P > 0.05 after 12 months). Mean resorption rate was 8.6 ± 3.7% at 12 months and 9.4 ± 4.1% at 36 months. FACE-Q satisfaction scores remained >80 across all domains without late decline. No graft displacement, irregularity, or donor-site morbidity was observed. CONCLUSIONS: The supramastoid fascia is a practical, minimally invasive autologous donor-site alternative for moderate dorsal augmentation, showing stable projection and high satisfaction through 36 months. Longer follow-up and multi-ethnic cohorts are warranted.
2. Oncologic adequacy and outcomes of open, transoral endoscopic, and robotic thyroidectomy for papillary thyroid carcinoma: a propensity score-matched analysis.
In a PSM analysis of 819 papillary thyroid carcinoma cases, transoral robotic thyroidectomy (TORT) achieved central lymph node yields comparable to open surgery and superior to TOETVA, with the lowest transient vocal cord palsy but longer operative time. Cosmetic advantages support TORT as an oncologically adequate scarless option.
Impact: Provides a direct three-way comparison clarifying oncologic adequacy and recovery trade-offs of scarless approaches, informing surgical choice beyond cosmetic preference alone.
Clinical Implications: For appropriately selected PTC, TORT can be offered as a scarless alternative with oncologic adequacy similar to open thyroidectomy; caution is warranted with TOETVA due to lower LN yield.
Key Findings
- Central lymph node yield: OT ≈ TORT and both > TOETVA (p<0.001).
- Hospital stay and operation-day pain were lowest with OT; TORT intermediate; TOETVA highest.
- Transient vocal cord palsy was lowest with TORT (1.6%); permanent palsy and hypocalcemia were similar across groups.
- Operative time was longest with TORT; Tg and RAI parameters did not differ between groups.
Methodological Strengths
- Large single-institution series with propensity score matching on 10 variables
- Direct three-arm comparison with multiple clinically relevant endpoints
- Balanced cohorts (n=124 each) post-matching
Limitations
- Retrospective design with potential residual confounding despite PSM
- Operative times and recovery metrics may reflect learning curve and center-specific protocols
- Long-term oncologic outcomes (recurrence/survival) not detailed
Future Directions: Prospective multicenter comparative trials capturing long-term oncologic and quality-of-life outcomes, including cost-effectiveness analyses of scarless approaches.
BACKGROUND: Transoral thyroidectomy, including transoral endoscopic thyroidectomy vestibular approach (TOETVA) and transoral robotic thyroidectomy (TORT), offers cosmetic advantages over conventional open thyroidectomy (OT). However, few studies have directly compared these three approaches in a single analysis. We evaluated the oncological adequacy and perioperative outcomes of OT, TOETVA, and TORT for papillary thyroid carcinoma using propensity score matching (PSM). METHODS: We retrospectively reviewed 819 consecutive patients who underwent OT (n = 559), TOETVA (n = 128), or TORT (n = 132) between 2016 and 2023. PSM was performed using 10 baseline clinicopathological variables to create three balanced cohorts (n = 124 each). The outcomes included central lymph node (LN) yield, complications, operative time, postoperative pain, hospital stay, and thyroglobulin and radioactive iodine (RAI) parameters. RESULTS: After matching, OT and TORT achieved similar central LN yields (7.1 ± 5.4 vs. 6.9 ± 2.9), both significantly higher than TOETVA (4.8 ± 2.8; p < 0.001). Hospital stay was shortest in the OT group (2.8 ± 1.7 days), intermediate in the TORT group (3.3 ± 0.7), and longest in the TOETVA group (4.0 ± 1.9; p < 0.001). Operation-day pain was lowest in the OT group (2.6 ± 0.5), intermediate in the TORT group (3.2 ± 0.9), and highest in the TOETVA group (3.8 ± 0.9; p < 0.001). Transient vocal cord palsy occurred least frequently in the TORT group (1.6%), followed by the TOETVA (7.3%) and OT (8.1%) groups (p = 0.056). The rates of permanent palsy and hypocalcemia were similar between the groups. The operative time was significantly longer in the TORT group than in the OT or TOETVA groups. Thyroglobulin levels and RAI parameters did not differ significantly between the groups. CONCLUSIONS: Both transoral approaches were safe and feasible. TORT achieved oncologic adequacy comparable to that of OT while providing scarless benefits despite prolonged operative time. TOETVA was feasible but was associated with a low LN yield. The choice of the surgical approach should be individualized according to oncological adequacy, recovery, and cosmetic preferences.
3. Safety Profile of 4,397 Consecutive Intravenous Sedations in Office-Based Esthetic Surgery: A Single-Center Retrospective Audit.
A single-center retrospective audit of 4,397 consecutive office-based aesthetic procedures under IV sedation reported zero major complications and low minor-event rates using ASA I–II selection, continuous monitoring, and weight-adjusted titration, even when directed by non-anesthesiologist surgeons.
Impact: Delivers rare, large-scale safety data for IV sedation in private cosmetic practice, directly informing protocols and credentialing in an expanding care setting.
Clinical Implications: Office-based aesthetic centers can achieve safe IV sedation by restricting to ASA I–II patients, maintaining continuous physiologic monitoring, and using weight-adjusted titration protocols; external validation is needed.
Key Findings
- Zero major complications across 4,397 consecutive IV sedation procedures.
- Low incidence of minor adverse events under standardized monitoring and titration.
- Safety achieved with non-anesthesiologist surgeons using strict ASA I–II selection.
- Propofol as first-line sedative; midazolam substituted for egg/soy allergy.
Methodological Strengths
- Large consecutive series minimizing selection bias
- Standardized monitoring and protocolized titration
- Clear eligibility (ASA I–II) and real-world practice setting
Limitations
- Single-center retrospective design without a control group
- Abstract lacks granular rates for specific minor complications
- Generalizability to higher-risk (ASA III+) patients is unknown
Future Directions: Prospective multicenter registries to benchmark specific adverse event rates, recovery metrics, and to assess applicability to broader risk profiles.
BACKGROUND: Intravenous sedation (IVS) is widely used in office-based esthetic surgery, yet large-scale safety data from private clinics are scarce. This study quantified IVS utilization and evaluated perioperative safety in a high-volume Japanese cosmetic center. METHODS: A retrospective review was conducted of all consecutive procedures performed under IVS between November 2020 and December 2024 at a single clinic. Eligibility was restricted to American Society of Anesthesiologists (ASA) class I-II patients. Propofol was the first-line sedative; midazolam was substituted for documented egg or soy allergy. Standard monitoring (ECG, noninvasive blood pressure, SpO CONCLUSIONS: Among 4,397 office-based esthetic procedures, IVS directed by non-anesthesiologist surgeons achieved a major complication rate of zero and a low incidence of minor events. Strict ASA I-II selection, continuous physiologic monitoring, and a weight-adjusted depth titration protocol can provide international-level safety in a private outpatient setting. Multicenter prospective studies are warranted to validate these findings and refine recovery benchmarks. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .